Definium Therapeutics then raised 700 million at a share price of $34, which is a 6% discount to yesterday’s closing price. The market cap of approximately 4.5 billion seems to be holding.
These DFTX MDD results seem to be generating a fair amount of investor hype. In a way, we are back to the situation of five years ago, where psychedelic drug/drugs really seem to offer—through a single treatment without the need for daily medication—a more effective and immediate symptom-relieving alternative than traditional antidepressants. Apparently, a 2±3±point MADRS delta has been typical for SSRI/SNRI drugs, and now an 8-point difference to placebo was presented. This was at the Phase 3 level, although it must be mentioned that this study had 149 patients, whereas, for example, Compass’s Phase 2b had around 250.
As I wrote earlier, I don’t believe that LSD is inherently a better antidepressant than psilocybin. As I see it, the difference between the MADRS deltas of Compass and Definium likely relates to the TRD versus MDD setup, i.e., patient selection.
Definium has clearly succeeded in exciting investors by choosing an indication where they can easily show better efficacy figures than old medication options. Furthermore, in theory, the indication covers a massive TAM (Total Addressable Market) - first-line treatment for depression! On the other hand, a staggering price will be asked for the drug, so health insurance coverage will almost certainly not be granted, at least in the early years, except in situations equivalent to TRD (it’s a different matter then, if patients and clinicians want to get LSD treatment for a patient, how easily two antidepressant trials can be “completed”…?).
An interesting “background” to the current moment is also provided by MAHA’s attack on traditional antidepressants.
Additionally, as a note, DFTX is conducting two relatively small Phase 3 trials in MDD and two in GAD, whereby they are pursuing marketing authorization for MDD+GAD—a TAM of tens of millions of US patients—with the same or smaller number of patients than Compass/TRD. On that basis, analysts’ price targets can be stretched almost indefinitely!
Compass, on the other hand, has been “toiling away” in perhaps a slightly boring fashion. They chose TRD as the indication, meaning they are studying efficacy and safety in the indication where coverage could practically be obtained right off the bat. It doesn’t show as exciting efficacy figures, nor does it show TAM estimates justifying similar price targets—but in practice, with the results seen, the probability of obtaining marketing authorization is considered likely. They have received Breakthrough Therapy Designation (CNPV/BTD), meaning authorization could come this year; efficacy and safety would be demonstrated for the population for which coverage is sought, which may ultimately be a very smart move. While efficacy figures excite investors in the short term and can certainly influence clinicians’ decisions, for drugs currently on the market, almost no doctor seems to remember the specific efficacy figures from clinical trials once the marketing authorizations are granted and the drug becomes established in use…
Will CMPS’s market cap catch up to Definium’s, for example, over a six-month timeframe…? 1.7 billion versus 4.5 billion at the moment…
Let’s add the specs of the patient material from the Definium study for comparison:
Here (from earlier in the thread) is one image of Compass’s patients. Symptom scores are not higher, but the disease progression is more chronic: